In vivo optical molecular imaging (OMI) is poised to move into clinical use as one of the key tools in personalized medicine, complementing more established imaging tools such as CT and MRI. Growth of equipment sales is on track to reach $400 million in 2014 and nearly $1 billion by the end of the decade.